GSK launches OTC Flonase Sensimist fluticasone furoate nasal spray in US

GSK Consumer Healthcare has announced the US launch of Flonase Sensimist fluticasone furoate nasal spray for the once-daily treatment of seasonal and perennial allergy symptoms. The FDA approved Flonase Sensimist, an over-the-counter version of Veramyst, in August 2016.

GSK has been marketing an OTC fluticasone propionate nasal spray as Flonase Allergy Relief in the US since February 2015.

GSK Senior Brand Manager for Flonase Jennifer Nadelson commented, “GSK Consumer Healthcare has a strong heritage in discovering and developing respiratory products to meet patient needs worldwide. With Flonase Sensimist, we’re proud to offer allergy sufferers an additional product option providing more complete symptom relief in a new, unique, user-friendly device.”

Read the GSK press release.